How can Alzheimer's disease blood‐based biomarkers reach clinical practice?
Early symptomatic Alzheimer's disease (AD) diagnosis improves treatment strategy and lowers costs.Currently available biomarkers are not widely used across all clinical settings.Blood-based biomarkers (BBMs) could be a cost-effective, minimally invasive alternative.BBMs could accelerate an accurate AD diagnosis.There are barriers to the inclusion of BBMs in clinical practice.
Authors
- Robert Perneczky (ORCID: https://orcid.org/0000-0003-1981-7435)
- Sebastian Palmqvist (ORCID: https://orcid.org/0000-0002-9267-1930)
- Wiesje M. van der Flier (ORCID: https://orcid.org/0000-0001-8766-6224)
- Oskar Hansson (ORCID: https://orcid.org/0000-0001-8467-7286)
- Frances‐Catherine Quevenco (ORCID: https://orcid.org/0000-0003-1467-6880)
- James A. Hendrix (ORCID: https://orcid.org/0000-0002-3752-0857)
- Takeshi Iwatsubo (ORCID: https://orcid.org/0000-0003-1160-8129)
- Charlotte Elisabeth Teunissen (ORCID: https://orcid.org/0000-0002-4061-0837)
- Marc Suárez‐Calvet (ORCID: https://orcid.org/0000-0002-2993-569X)
- Michelle M. Mielke (ORCID: https://orcid.org/0000-0001-7177-1185)
- Stéphane Epelbaum (ORCID: https://orcid.org/0000-0003-4059-2891)
- Jiong Shi (ORCID: https://orcid.org/0000-0002-8684-4268)
Institutions
- University of Science and Technology of China (CN)
- Bunkyo University (JP)
- Eli Lilly (United States) (US)
- Malmö University (SE)
- Anhui Medical University (CN)
- German Center for Neurodegenerative Diseases (DE)
- LMU Klinikum (DE)
- Pasqual Maragall Foundation (ES)
- Amsterdam Neuroscience (NL)
- Munich Cluster for Systems Neurology (DE)
- Hospital Del Mar (ES)
- First Affiliated Hospital of Anhui Medical University (CN)
- Skåne University Hospital (SE)
- Amsterdam University Medical Centers (NL)
- Wake Forest University (US)
- Imperial College London (GB)
- The University of Tokyo (JP)
- Ludwig-Maximilians-Universität München (DE)
- University of Sheffield (GB)
Publication Details
- Journal
- Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1002/dad2.70207
- Citations
- 1
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Eli Lilly and Company
- Sanofi
- Biogen
- Celgene
- EU Joint Programme – Neurodegenerative Disease Research
- European Federation of Pharmaceutical Industries and Associations
- Roche Nederland
- European Commission
- ZonMw
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek
- Eisai
- Novo Nordisk
- Hersenstichting
- Stichting Dioraphte
- Alzheimer Nederland
- GIESKES-STRIJBIS FONDS
- HORIZON EUROPE Framework Programme